Pluristem Therapeutics Inc. and American Stock Transfer & Trust Company, LLC, as Warrant AgentWarrant Agent Agreement • May 6th, 2019 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances) • New York
WARRANT AGENT AGREEMENT, dated as of April 4, 2019 (“Agreement”), between Pluristem Therapeutics Inc., a Nevada corporation (the “Company”), and American Stock Transfer & Trust Company, LLC, a New York limited liability trust company (the “Warrant Agent”).
PLURISTEM THERAPEUTICS INC. 27,142,858 Shares and Warrants to purchase 27,142,858 Shares UNDERWRITING AGREEMENTUnderwriting Agreement • May 6th, 2019 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances) • New York
PLURISTEM THERAPEUTICS INC., a Nevada corporation (the “Company”), proposes to issue and sell to Ladenburg Thalmann & Co. Inc. (the “Representative”) and the other underwriters listed on Schedule I hereto (collectively, with the Representative, the “Underwriters”), pursuant to and in accordance with the terms and conditions of this underwriting agreement (the “Agreement”) in a public offering (the “Offering”), an aggregate of 27,142,858 shares (the “Shares”) of its common stock, par value $0.00001 per share (the “Common Stock”), and warrants (each whole warrant, a “Warrant”) to purchase up to an aggregate of 27,142,858 shares of Common Stock. The Shares to be sold by the Company are called the “Firm Shares.” The Firm Shares and the Warrants will be sold as units (the “Units”), with each Unit consisting of one Share and a Warrant to purchase one Share. In addition, the Company has granted to the Underwriters an option to purchase up to an additional 1,428,571 Shares as provided in Secti
Employment AgreementEmployment Agreement • May 6th, 2019 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances)
WHEREAS, the Employee has been employed by the Company since May 1 2013 and the Employee and the Company seek to enter into this Employment Agreement (the “Agreement”) to set forth the terms of the Employee’s employment as the Company’s Chief Financial Officer,; and
SUBSCRIPTION AGREEMENTSubscription Agreement • May 6th, 2019 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances)
This Subscription Agreement (this “Subscription”) is dated as of April 4, 2019, by and between Pluristem Therapeutics Inc., a Nevada corporation (the “Company”), and the investor identified on the signature page hereto (including its successors and assigns, the “Investor”).
